Efficient in vivo delivery of siRNA to the liver by conjugation of α-tocopherol

Molecular Therapy

Volumn 16, Issue 4, 2008, Pages 734-740

  Nishina, Kazutaka ^a   Unno, Toshinori ^a   Uno, Yoshitaka ^a   Kubodera, Takayuki ^a   Kanouchi, Tadashi ^a   Mizusawa, Hidehiro ^a   Yokota, Takanori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN A; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DOSE RESPONSE; DOWN REGULATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; GENE SILENCING; GENE STRUCTURE; IN VIVO STUDY; LIPID LIVER LEVEL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN STRUCTURE; PROTEIN TARGETING; RNA INTERFERENCE;

EID: 41149179660     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.14     Document Type: Article

References (29)

1. Davidson, BL and Harper, SO (2005). Viral delivery of recombinant short hairpin RNAs. Methods Enzymol 392: 145-173.
2. McCaffrey, AP, Meuse, L, Pham, TT, Conklin, DS, Hannon, GJ and Kay, MA (2002). RNA interference in adult mice. Nature 418: 38-39.
3. Hino, T, Yokota, T, Ito, S, Nishina, K, Kang, YS, Mori, S et al. (2006). In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem Biophys Res Commun 340: 263-267.
4. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
5. Yokota, T, Iijima S, Kubodera, T, Ishii, K, Katakai, Y, Ageyama, N et al. (2007). Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun 361: 294-300.
6. Spagnou, S, Miller, AD and Keller, M (2004). Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43: 13348-13356.
7. Baigude, H, McCarroll, J, Yang, CS, Swain, PM and Rana, TM (2007). Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem Biol 2: 237-241.
8. Rozema, DB, Lewis, DL, Wakefield, DH, Wong, SC, Klein, JJ, Roesch, PL et al. (2007). Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 104 12982-12987.
9. Sato, A, Takagi, M, Shimamoto, A, Kawakami, S and Hashida, M (2007). Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28: 1434-1442.
10. Kim, SI, Shin, D, Choi, TH, Lee, JC, Cheon, GJ, Kim, KY et al. (2007). Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-1. Mol Ther 15: 1145-1152.
11. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
12. Kappus, H and Diplock, AT (1992). Tolerance and safety of vitamin E: A toxicological position report. Free Radic Bliol Med 13: 55-74.
13. Rigotti, A (2007). Absorption, transport, and tissue delivery of vitamin E, Mol Aspects Med 28: 423-436.
14. Zingg, JM (2007). Vitamin E: An overwiew of major research directions. Mol Aspects Med 28: 400-422.
15. Rose, SD, Kim, DH, Amarzguibui, M, Heidel, JD, Collingwood, MA, Davis, ME et al. (2005). Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res 33: 4140-4156.
16. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
17. Chiu, YL and Rana, TM (2003). siRNA function in RNAi: A chemical modification analysis. RNA 9: 1034-1048.
18. Czauderna, F, Fechtner, M, Dames, S, Aygün, H, Klippel, A, Pronk, GJ et al. (2003). Structural variations and stabilising modificatious of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31 2765-2716.
19. Miyoshi, K, Tsukumo, H, Nagami, T, Siomi, H and Siomi, MC (2005). Slicer function of Drosophila Argonautes and its involvement in RISC formation. Genes Dev 19: 2837-2848.
20. Judge; AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505.
21. Sioud, M, Furset, G and Cekaite, L (2007). Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. Biochem Biophys Res Commun 361: 122-126.
22. Aftergood, L and Alfin-Slater, RB (1978). Effect of administration of α- and γ-tocopherol on tissue distribution and red cell hemolysis in rats. Int J Vitam Nutr Res 48: 32-37.
23. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157.
24. Chen, Z, Fitzgerald, RL, Averna, MR and Schonfeld, G (2000). A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides. J Biol Chem 275: 32807-32815.
25. Raabe, M, Véniant, MM, Sullivan, MA, Zlot, CH, Björkegren, J, Nielsen, LB et al. (1999). Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 103: 1287-1298.
26. Minehira-Castelli, K, Leonard, SW, Walker, QM, Traber, MG and Young, SG (2006). Absence of VLDL secretion does not affect α-tocopherol content in peripheral tissues. J Lipid Res 47: 1733-1738.
27. Food and Nutrition Board, National Academy of Sciences, National Research Council (1989). Recommended Dietary Allowances 10th edn. National Academy Press: Washington, DC, pp 99-107.
28. Robbins, M, Judge, A, Liang, L, McClintock, K, Yaworski, E and MacLachlan, I (2007). 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Their 15: 1663-1669.
29. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007.